FAAH

Cat. No.

A74628

CAS No.

1304778-15-1

TC-F2

TC-F2 is a reversible non-covalent inhibitor of fatty acid amide hydrolase (FAAH), exhibiting an IC50 of 28 nM. By modulating FAAH activity, TC-F2 is pertinent for research focused on various human diseases, including cancer, pain, inflammation, as well as neurological, metabolic, and cardiovascular disorders. This compound provides a valuable tool for investigating the therapeutic potential of FAAH inhibition in these areas.

Cat. No.

A74632

CAS No.

1010096-65-7

FAAH/MAGL-IN-5

FAAH/MAGL-IN-5 is a potent inhibitor of both fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), exhibiting equipotent inhibitory activity with an IC50 of 1.2 nM. This dual inhibition results in enhanced endocannabinoid levels, contributing to neuroprotective effects. FAAH/MAGL-IN-5 is valuable in research applications focused on pain management, neurodegenerative disorders, and the modulation of the endocannabinoid system.

Cat. No.

A74633

CAS No.

1515855-85-2

AKU-005

AKU-005 is a dual inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), exhibiting IC50 values of 63 nM and 389 nM for rat and human FAAH, respectively. This compound demonstrates significant potential in the study of trigeminal hyperalgesia and related pain pathways, making it a valuable tool for researchers investigating endocannabinoid signaling and pain modulation mechanisms.

Cat. No.

A74634

CAS No.

86855-26-7

AM 374

AM 374 is a potent inhibitor of fatty acid amide hydrolase (FAAH), demonstrating an IC50 value of 13 nM for amidase activity inhibition. This compound is utilized in research focused on neurological diseases, contributing to the understanding of endocannabinoid signaling pathways and their therapeutic potential in various conditions.

Cat. No.

A74636

CAS No.

256383-45-6

FAAH/MAGL-IN-4

FAAH/MAGL-IN-4 is a selective inhibitor of fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL), exhibiting IC50 values of 9.1 nM and 7.9 μM, respectively. This compound plays a critical role in modulating endocannabinoid signaling pathways, making it valuable for investigating pain mechanisms and central nervous system disorders. Its potent inhibitory activity supports research in neurology and pain management applications.

Cat. No.

A74637

CAS No.

2244136-58-9

Irafamdastat

Synonyms: BMS-986368; CC-97489; ABX-1772

Irafamdastat is a potent inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), exhibiting IC50 values of ≤ 100 nM for human FAAH and 100 nM-1 µM for human MAGL. This compound has demonstrated antiepileptic effects and is valuable for research into pain management, neuroprotection, and anxiety. Its dual inhibition of FAAH and MAGL positions it as a significant tool for exploring endocannabinoid system modulation in various therapeutic contexts.

Cat. No.

A74638

CAS No.

1143578-94-2

FAAH-IN-6

FAAH-IN-6 is a potent fatty acid amide hydrolase (FAAH) inhibitor that effectively crosses the blood-brain barrier, exhibiting IC50 values of 0.72 nM and 0.28 nM for human and rat FAAH, respectively. This compound demonstrates significant dose-dependent analgesic effects in preclinical models of neuropathic and inflammatory pain, making it valuable for research on pain management and therapeutic interventions targeting the endocannabinoid system.

Cat. No.

A74640

CAS No.

847361-96-0

N-(3-Methoxybenzyl)Palmitamide

N-(3-Methoxybenzyl)Palmitamide is an inhibitor of fatty acid amide hydrolase (FAAH), which is crucial in the regulation of endocannabinoid signaling. This compound exhibits significant anti-inflammatory and analgesic properties, making it a valuable tool for research into pain relief and the treatment of central nervous system degenerative disorders. Its potential applications extend to studying the therapeutic effects of endocannabinoids in various biological contexts.

Cat. No.

A74641

CAS No.

1394894-41-7

JNJ-40355003

JNJ-40355003 is a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. It effectively enhances the levels of endocannabinoids, contributing to its biological activity in the modulation of pain, anxiety, and inflammation. This compound is valuable for research in cannabinoid signaling and therapeutic applications targeting the endocannabinoid system.

Cat. No.

A74642

CAS No.

887264-44-0

JP83

JP83 is an irreversible inhibitor of fatty acyl amide hydrolase (FAAH), demonstrating an IC50 of 1.6 nM in competitive activity-based protein profiling (ABPP) assays. This compound is valuable for studying the role of FAAH in regulating endocannabinoid signaling and its implications in pain modulation and various neurological disorders. Researchers utilize JP83 to elucidate the mechanistic pathways of FAAH inhibition and explore potential therapeutic applications in cannabinoid pharmacology.

Cat. No.

A74643

CAS No.

666860-59-9

SSR411298

SSR411298 is a selective and reversible inhibitor of fatty acid amide hydrolase (FAAH). This compound demonstrates significant potential in modulating endocannabinoid levels, making it a valuable tool for research related to post-traumatic stress disorder (PTSD) and other neuropsychiatric conditions. Its oral bioavailability further enhances its utility in various preclinical studies.

Cat. No.

A74644

CAS No.

887264-45-1

JP104

JP104 is an irreversible inhibitor of fatty acid amide hydrolase (FAAH), exhibiting a potent pIC50 of approximately 8. This compound effectively modulates endocannabinoid levels, making it a valuable tool for studying pain management, neurobiology, and potential therapeutic applications in anxiety and stress-related disorders. Its mechanism of action provides unique insights into the biological pathways influenced by FAAH inhibition.

Cat. No.

A74646

CAS No.

906737-25-5

ASP 8477

ASP 8477 is a selective inhibitor of fatty acid amide hydrolase (FAAH), demonstrating IC50 values of 3.99 nM for human FAAH-1, 1.65 nM for the FAAH-1 (P129T) variant, and 57.3 nM for FAAH-2. This compound exhibits central nervous system activity, making it valuable in analgesia research. Its potent inhibition of FAAH positions ASP 8477 as a significant tool for studying pain modulation and endocannabinoid signaling pathways.

Cat. No.

A74647

CAS No.

898235-65-9

PF-622

PF-622 is a selective inhibitor of fatty acid amide hydrolase (FAAH), which plays a crucial role in the endocannabinoid system. This compound is utilized in research focused on analgesic, anxiolytic, and antidepressant effects, making it valuable for studies exploring pain management and mood disorders. Its ability to modulate endocannabinoid levels enables investigation into therapeutic strategies for various neurological conditions.

Cat. No.

A74648

CAS No.

2848719-34-4

FAAH/MAGL-IN-3

FAAH/MAGL-IN-3 is an irreversible inhibitor targeting fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) with IC50 values of 179 nM and 759 nM, respectively. This dual inhibitor is valuable for studying endocannabinoid metabolism and its implications in various physiological and pathological processes. Notably, FAAH/MAGL-IN-3 demonstrates low permeability in the PAMPA assay, indicating a potential for selective activity in research applications.

Cat. No.

A74649

CAS No.

875014-22-5

3-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone

3-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone is a potent inhibitor of fatty acid amide hydrolase (FAAH) with a pI50 of 5.89. This compound exhibits significant activity against endocannabinoids and lipid mediators, making it relevant for studies in pain management, inflammation, and cannabinoid signaling pathways. Its limited affinity for cannabinoid receptors CB(1) and CB(2) allows for targeted research into FAAH-related physiological processes without direct receptor modulation.

Cat. No.

A74650

CAS No.

1696401-38-3

FAAH/cPLA2α-IN-1

FAAH/cPLA2α-IN-1 is a dual inhibitor targeting fatty acid amide hydrolase (FAAH) and cytosolic phospholipase A2 alpha (cPLA2α), exhibiting IC50 values of 32 nM and 47 nM, respectively. This compound demonstrates potential anti-inflammatory properties by modulating lipid signaling pathways, making it valuable for research into pain management, neuroprotection, and inflammatory responses. Its use in various preclinical studies may provide insights into the therapeutic potential of FAAH and cPLA2α inhibition.

Cat. No.

A74651

CAS No.

1006604-91-6

MM-433593

MM-433593 is a selective inhibitor of fatty acid amide hydrolase-1 (FAAH-1), targeting the endocannabinoid system to modulate pain and inflammation pathways. It demonstrates effective pharmacokinetic properties, including a biphasic elimination profile characterized by a rapid distribution and a slower elimination phase. With moderate oral bioavailability (14-21%), MM-433593 undergoes metabolism primarily through the oxidation of its indole ring's methyl group, yielding various sulfate, glucuronide, and glutathione-conjugated metabolites, making it a valuable tool for investigating FAAH-related biological processes and therapeutic applications.

Cat. No.

A74652

CAS No.

1346169-63-8

SA57

SA57 is a selective inhibitor of fatty acid amide hydrolase (FAAH), exhibiting IC50 values of 3.2 nM and 1.9 nM for mouse and human FAAH, respectively. In addition to its primary target, SA57 demonstrates inhibitory effects on 2-arachidonoylglycerol hydrolases, including monoacylglycerol lipase (MAGL) with IC50s of 410 nM and 1.4 μM for mouse and human, as well as mouse α/β-hydrolase domain-containing protein 6 (mABHD6) with an IC50 of 850 nM. This compound is valuable for research related to the endocannabinoid system and pain management studies.

Cat. No.

A74653

CAS No.

2765077-82-3

FAAH/MAGL-IN-2

FAAH/MAGL-IN-2 is a potent, reversible inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). It exhibits IC50 values of 11 nM and 36 nM for FAAH and MAGL, respectively, demonstrating significant inhibitory potency. This compound effectively crosses the blood-brain barrier, making it a valuable tool for investigating the role of endogenous lipids in neuropathic pain while minimizing locomotion impairment. Its selective inhibition profile facilitates research into therapeutic approaches for pain management and related disorders.

Cat. No.

A74654

CAS No.

3037600-36-2

FAAH-IN-7

FAAH-IN-7 is a potent and reversible inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 8.29 nM. This compound effectively reduces oxidative stress in 1321N1 astrocytes and demonstrates significant neuroprotective effects in ex vivo models of neuroinflammation. FAAH-IN-7 is valuable for studies involving neuroprotection and modulation of the endocannabinoid system in various neurological research applications.

Cat. No.

A74655

CAS No.

195140-79-5

URB532

URB532 is a selective inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 396 nM. This compound effectively elevates the levels of key endogenous lipid mediators, including arachidonic acid acetamide (AEA), palmitoylethanolamide (PEA), and oleamide (OEA) in the rat brain. URB532 has demonstrated notable anxiolytic and analgesic effects, making it a valuable tool for research on pain and anxiety modulation.

Cat. No.

A74656

CAS No.

1338575-38-4

FAAH-IN-5

FAAH-IN-5 is an irreversible inhibitor of fatty acid amide hydrolase (FAAH) with a reported IC50 of 10.5 nM, demonstrating relative selectivity. This compound is suitable for research applications focused on endocannabinoid signaling pathways and pain modulation. Despite its potency, FAAH-IN-5 exhibits low permeability in the Parallel Artificial Membrane Permeability Assay (PAMPA), making it an important tool for studies in pharmacokinetics and bioavailability.

Cat. No.

A74657

CAS No.

904672-77-1

URB694

URB694 is a carbamate inhibitor of fatty acid amide hydrolase (FAAH) that irreversibly carbamoylates the catalytic serine residue in the FAAH active site. This compound exhibits notable antidepressant-like effects and offers potential cardioprotective properties. URB694 can also be utilized in the synthesis of 11C-Carbonyl-URB694, facilitating in vivo positron emission tomography (PET) imaging studies aimed at elucidating FAAH activity in the brain.

Cat. No.

A74659

CAS No.

1207745-58-1

MK-4409

MK-4409 is a potent inhibitor of fatty acid amide hydrolase (FAAH) that demonstrates significant anti-inflammatory properties. It is primarily utilized in research focusing on inflammatory and neuropathic pain mechanisms. The compound’s ability to modulate endocannabinoid levels makes it a valuable tool for studying pain pathways and potential therapeutic interventions.